{"id":"W4311025044","doi":"10.1016/j.annonc.2022.11.012","title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"Pharmacyclics; Merck Sharp and Dohme; EMD Serono; Genentech; Ipsen; Universidad de Navarra; Basilea Pharmaceutica; Astellas Pharma; Eisai; Seagen; Foundation Medicine; Flatiron Health; G1 Therapeutics; GlaxoSmithKline; UroGen Pharma; Bavarian Nordic; Silverback Therapeutics; Pfizer; Innovent Biologics; Incyte; BeiGene; Mirati Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Celldex Therapeutics; Advanced Accelerator Applications; National Institutes of Health; Natera; Regeneron Pharmaceuticals; Merck KGaA; Endocyte; Gilead Sciences; Exelixis; Sanofi; Amgen; Allergan; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Internal medicine; Expanded access; Cancer; Immunotherapy; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007178265,0.0006895432,0.00131253,0.000506153,0.0003761167,0.0007311612,0.0007364177,0.001024819,0.003113602],"category_scores_gemma":[0.004197045,0.0002336358,0.003020912,0.0005286545,0.0004636984,0.001140901,0.0006466096,0.001315918,0.000436619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001123011,"about_ca_system_score_gemma":0.0008331879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007078156,"about_ca_topic_score_gemma":0.001185642,"domain_scores_codex":[0.997542,0.001173536,0.0003024186,0.0003849127,0.0003179352,0.0002792072],"domain_scores_gemma":[0.9961491,0.000949308,0.001485713,0.0004037276,0.000395525,0.0006167293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7381211,0.01006434,0.0977753,0.002937622,0.01278672,0.0003215137,0.0003477063,0.005109827,0.01358019,0.0004021866,0.006243709,0.1123098],"study_design_scores_gemma":[0.1439567,0.3586008,0.458772,0.0005117226,0.0127047,0.001066635,0.0002741746,0.003264322,0.008862845,0.0004244276,0.0114305,0.0001311786],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855734,0.008642845,0.0003411428,0.0002208966,0.00004703662,0.0005865127,0.002771982,0.00002789436,0.001788403],"genre_scores_gemma":[0.9933133,0.001283537,0.0002884412,0.0002420758,0.00007116343,0.0003378404,0.003463084,0.000006902268,0.0009936793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007178265,"threshold_uncertainty_score":0.03796273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05259067387769641,"score_gpt":0.3455086135433258,"score_spread":0.2929179396656294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}